Main Therapeutic Uses

Пергонал is a medication containing gonadotropins, specifically follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It is primarily used in reproductive medicine to address hormonal imbalances that affect fertility in both women and men.

Female Infertility and Ovulation Induction

The primary application of Пергонал is to stimulate the ovaries in women who are experiencing difficulty conceiving due to ovulatory dysfunction. This includes:

• Induction of Ovulation: For women who do not ovulate or who have irregular ovulation cycles (such as those with Polycystic Ovary Syndrome), the medication helps stimulate the development and maturation of a single dominant follicle.
• Controlled Ovarian Stimulation: In the context of Assisted Reproductive Technologies (ART), such as In Vitro Fertilization (IVF), the medication is used to induce the growth of multiple follicles simultaneously. This allows for the collection of several eggs to increase the chances of successful fertilization and embryo development.

Male Infertility and Spermatogenesis

In men, Пергонал is used to treat certain types of infertility caused by a deficiency in gonadotropins, a condition known as hypogonadotropic hypogonadism. Its primary functions include:

• Stimulation of Sperm Production: By providing the necessary FSH and LH, the medication supports the development of sperm within the testes.
• Hormonal Balance: It helps restore the endocrine environment necessary for reproductive health when the pituitary gland is not producing sufficient natural hormones.

Benefits and Clinical Goals

The goal of treatment with Пергонал is to replicate or enhance natural reproductive processes that are otherwise absent or insufficient.

• Follicular Development: In women, the medication promotes the healthy growth of follicles to a size appropriate for rupture and egg release.
• Improved Reproductive Potential: By correcting hormonal deficits or augmenting the body's natural response, the medication provides the biological foundation required for conception to occur, whether through natural intercourse or clinical procedures.
• Targeted Hormone Replacement: For individuals with specific pituitary or hypothalamic deficiencies, it acts as a direct replacement for the missing signals needed to activate the gonads.

Eligibility for Пергонал (Menotropin)

The use of this medicine is strictly defined by regulatory documents, which establish specific criteria for who is eligible for treatment and who is absolutely prohibited from using it (contraindicated).

Classification	Population Eligibility	Status as per Regulatory Labeling
Target Population	Adult women of reproductive age undergoing ovulation induction or ART. Adult men with hypogonadotropic hypogonadism.	Allowed
Absolute Contraindications	Women with primary ovarian failure (high FSH levels), known pregnancy, or prior hypersensitivity to menotropins.	Contraindicated

Regulatory Non-Eligibility Rules

Menotropin must not be used in patients presenting with certain hormone-sensitive conditions, as defined in official prescribing information:

• Tumors: Patients with sex hormone-dependent tumors of the reproductive tract and accessory organs, or tumors of the pituitary gland or hypothalamus.
• Existing Conditions: Abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement not due to Polycystic Ovary Syndrome (PCOS), and uncontrolled non-gonadal endocrinopathies (e.g., thyroid or adrenal dysfunction).

Use in Specific Populations

• Age: Safety and efficacy have not been established in pediatric or geriatric populations.
• Organ Function: Use is not established in patients with renal (kidney) or hepatic (liver) insufficiency.
• Lactation: Use is generally not recommended or is contraindicated during breastfeeding.

Interactions with other medicines and products

Lack of Formal Pharmacokinetic Interaction Data

The official prescribing information for menotropins, the active substance in Пергонал, explicitly states that no dedicated drug-drug interaction studies have been conducted in humans. This regulatory finding means there are no documented interaction profiles for metabolic pathways, such as CYP-mediated enzyme systems, or for transporter proteins that might alter the plasma concentration (exposure) or clearance of Menotropin.

Interactions with Gonadotropins

Interactions are formally documented as necessary co-administration constraints when using other fertility agents with additive hormonal effects:

• Human Chorionic Gonadotropin (hCG): Administration of hCG to induce final follicular maturation is sequential, but the regulatory label requires that hCG must be withheld if safety monitoring on the last day of menotropins therapy suggests an increased risk of Ovarian Hyperstimulation Syndrome (OHSS).
• Urofollitropin (Purified FSH): Co-administration with urofollitropin is permitted, but the total combined daily dose of both products must not exceed 450 International Units, representing a quantitative administration restriction.

Non-Medicinal Interactions and Special Populations

No formal interactions with food, alcohol, or herbal products are documented in the official prescribing information. Furthermore, the pharmacokinetics and potential for altered drug exposure have not been established or studied in patients with renal or hepatic insufficiency, a restriction noted in the regulatory label.

Mechanism of Action

The drug's active components act as direct agonists for the Follicle-Stimulating Hormone Receptor (FSHR) and the Luteinizing Hormone Receptor (LHCGR), which are G protein-coupled receptors located on gonadal cells. This interaction functions as a direct agonist, initiating the signaling cascade within the target cells independent of pituitary regulation.

Receptor binding rapidly activates G-protein signaling, leading to the mobilization of the second messenger cyclic AMP (cAMP) and the activation of Protein Kinase A (PKA) inside the cell. This cascade drives the expression of enzymes, such as aromatase, that mediate the synthesis of steroid hormones.

The resulting PKA activity causes the proliferation of granulosa cells and promotes the production of estrogens and androgens (steroidogenesis) through the coordinated two-cell, two-gonadotropin mechanism. The physiological effect is the growth and maturation of multiple ovarian follicles and a resultant increase in serum estradiol levels, which are the observable physiological consequences of the mechanism.

How to Use Пергонал (Pergonal)

Administration of Пергонал (Menotropins) is guided by clinical guidelines and requires specialized medical supervision. The following describes the proper use of the medication.

---

Administration and Dosage

Usage Feature	General Guidelines
Route of Administration	Administered via Intramuscular (IM) or Subcutaneous (SC) injection.
Dosage Form	Supplied as a lyophilized powder that requires reconstitution prior to injection.
Standard Dosing	Therapy typically begins with a daily dose of 75 International Units (IU) of FSH and LH. This is administered once daily for a specified period (e.g., 7–12 days).
Dose Adjustments	The dose is personalized and may be adjusted by a healthcare professional based on ovarian response (e.g., follicular development) and serum estradiol levels, generally not more frequently than every 7 days.

---

Preparation and Procedural Steps

1. Reconstitution: The powder must be dissolved immediately before use using the sterile solvent provided in the package. The resulting solution must be visually inspected and should be clear.
2. Injection: The dose must be injected using sterile technique. Patients are instructed to rotate the injection site to minimize local reactions.
3. Treatment Conclusion: The daily Пергонал injections must be stopped once appropriate follicular development is achieved. The treatment is then completed by administering a single dose of Human Chorionic Gonadotropin (hCG) 24 to 48 hours after the last Пергонал injection.

This two-part procedural structure—daily menotropin injections followed by a specific hCG trigger—is an established protocol to complete the ovulation induction process.

Research Evidence: Menotropins (Pergonal)

Pergonal is a brand name for menotropins (Human Menopausal Gonadotropin or hMG), a preparation containing equal amounts of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) extracted from the urine of postmenopausal women. Research on this formulation focuses primarily on its use in Assisted Reproductive Technology (ART), particularly for stimulating ovarian follicular development.

Efficacy and Outcomes in ART

Clinical trials have established the effectiveness of hMG for controlled ovarian stimulation and ovulation induction. Studies often compare hMG preparations to newer recombinant (laboratory-produced) gonadotropins, such as recombinant FSH (rFSH).

Research Focus	Summary of Findings
hMG vs. rFSH (Efficacy)	Multiple systematic reviews and meta-analyses suggest that highly purified hMG and rFSH are generally associated with similar rates of ongoing pregnancy or live birth in women undergoing IVF/ICSI, particularly in the general infertile population.
Follicular Response	Some trials have reported that treatment with rFSH may result in a higher number of oocytes retrieved compared to hMG, though this difference does not consistently translate into a higher live birth rate.

---

Safety Profile

Clinical data indicates that the primary safety concerns associated with menotropin use are consistent across different gonadotropin formulations:

• Ovarian Hyperstimulation Syndrome (OHSS): The incidence of OHSS is a major safety consideration, and rates have been explored across both urinary and recombinant preparations, with some studies suggesting similar rates.
• Multiple Pregnancy: The use of menotropins for ovarian stimulation is associated with an elevated risk of multiple gestations (twins, triplets, etc.). Patients are advised to consult their healthcare provider regarding this risk prior to treatment.

Common questions about Пергонал (FAQ)

Q: How does Pergonal differ from other ovarian stimulation medicines?

Pergonal is a urinary-derived gonadotropin, meaning its active components are sourced from urine. It provides a unique combination of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in a 1:1 ratio. This differs from some other drugs that may contain only recombinant FSH, providing a different hormonal mix as defined in the official product information.

---

Q: Why must Pergonal be administered by injection and not taken as pills?

Pergonal contains active ingredients known as glycoproteins, which are protein-based hormones. If these proteins were taken orally, they would be broken down and rendered ineffective by the body’s digestive system. Therefore, the medication is formulated as a powder for injection and is the route mandated by regulatory instructions for the medication to be active.

---

Q: Are there long-term risks associated with taking Pergonal for multiple cycles?

Official prescribing information highlights a potential for an increased risk of ovarian cancer, particularly if the medication is received more than one time to achieve a pregnancy. Consultation with a healthcare provider regarding this potential risk is necessary according to official guidance.

---

Q: Are allergic reactions to Pergonal possible and how might they appear?

Hypersensitivity (a severe allergic reaction) to menotropins is listed as a contraindication for use. While official side effect lists do not frequently classify general allergy symptoms like common rash or itching, any sign of a severe reaction requires immediate medical attention.

---

Q: Can taking other medications affect the action of Pergonal?

Regulatory instructions state that formal, dedicated drug-drug interaction studies have not been conducted with this medicine. Official documents recommend the disclosure of all concurrent medications to the healthcare provider due to the lack of dedicated interaction studies.

---

Q: Do any vitamins or dietary supplements affect the effectiveness of Pergonal?

Official regulatory documents indicate that there are no formal documented interactions with food, alcohol, or herbal products. Guidance from a medical professional is necessary regarding the use of vitamins or supplements during treatment, as their influence on hormonal therapy is not formally established.

---

Q: Is Pergonal used only for IVF or for other fertility procedures too?

Pergonal is used both for the stimulation of multiple follicles during Assisted Reproductive Technology (ART) procedures like IVF, and for the induction of ovulation in women who have difficulty ovulating on their own. It is an established treatment for different types of infertility and reproductive support.

---

Q: How quickly does Pergonal start working after the first injection?

The physiological effect of Pergonal, which is follicular growth, typically develops gradually over the full treatment course. The cycle of injections usually lasts between 7 and 12 days. The effect is monitored by the healthcare team through blood tests and ultrasound, rather than by a single quick reaction immediately after one injection.

---

Q: How long does one cycle of Pergonal treatment typically last?

A standard course of Pergonal injections typically lasts for 7 to 12 days. The individual duration of treatment is personalized by a doctor based on the patient's ovarian response, which is assessed during regular monitoring visits.

---

Q: What blood test results indicate that Pergonal is working?

Doctors monitor the treatment primarily by using blood tests to check the level of serum estradiol, a key hormone. This blood work is used alongside ultrasound imaging to evaluate the growth and maturation of the ovarian follicles.

---

Q: Does the risk of ectopic pregnancy increase with the use of Pergonal?

Official instructions warn that women who conceive following Assisted Reproductive Technology (ART) procedures have a higher risk of ectopic (tubal) pregnancy, which is a serious medical complication.

---

Q: What is known about the link between Pergonal and an increased risk of ovarian cancer?

Regulatory documents state that the use of menotropins may increase the risk of developing ovarian cancer, particularly if the medicine has been used more than one time to achieve pregnancy. This risk is a subject that requires consultation with a medical professional.

---

Q: Can Pergonal side effects appear after treatment has been completed?

Yes, official product information confirms that some side effects can still appear or even worsen after the last injection of the medicine. This is most relevant for symptoms associated with Ovarian Hyperstimulation Syndrome (OHSS).

---

Q: Does Pergonal cause weight gain or swelling (edema)?

Rapid weight gain and abdominal distension (bloating) are listed in regulatory documents as serious symptoms associated with the onset of Ovarian Hyperstimulation Syndrome (OHSS). The presence of these symptoms necessitates immediate medical attention and evaluation by the healthcare team.

---

Q: Can Pergonal cause a skin reaction other than at the injection site?

While reactions at the injection site (such as pain or bruising) are common, the development of general skin issues is less common. Any generalized skin reaction could be a sign of a hypersensitivity or allergic response, as noted in regulatory materials.

---

Q: Does Pergonal affect the menstrual cycle apart from stimulation?

Official information lists changes to the menstrual cycle among the less common adverse reactions. While the main goal of the medicine is stimulation, minor alterations to the cycle can occur.

---

Q: Can taking Pergonal cause hot flashes?

Yes, regulatory summaries list the experience of a feeling of warmth, or redness of the face, neck, and upper body, among the less common side effects. This sensation is known clinically as a hot flash.

---

Q: How often does ovarian torsion occur during stimulation?

Ovarian torsion (twisting of the ovary) is a rare but serious complication. Its risk increases when the ovaries become significantly enlarged, such as with Ovarian Hyperstimulation Syndrome (OHSS). Regulatory materials describe it as a rare event that typically presents with sudden, severe abdominal pain, nausea, and vomiting.

---

Q: Does the risk of miscarriage increase after Pergonal treatment?

Official instructions indicate that the rate of miscarriage (spontaneous abortion) is higher for patients undergoing Assisted Reproductive Technology (ART) compared to natural conception. This increased risk is a consideration for all pregnancies resulting from ART procedures.

How to Store and Dispose of Pergonal (Menotropins for Injection)

Official regulatory guidelines define strict handling, storage, and disposal rules for this medication.

---

Storage Requirements

• Unused Powder: Store the unopened vial in the original carton to protect it from light. Follow the specific temperature range (e.g., room temperature or refrigeration) indicated on the package label. Do not freeze the product.
• Reconstituted Solution: The mixed solution is intended for immediate, single-use administration only. Any unused portion must be discarded immediately as stability is not maintained.

---

Disposal Instructions

• Needles and Syringes: All used needles and syringes must be discarded immediately into a designated, puncture-resistant sharps disposal container.
• Unused Medicine: Safely dispose of expired or unwanted medicine via an official drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance (like coffee grounds) and place it in a sealed container in the household trash. Keep all medicine and sharps out of the reach of children.